Semaglutide vs liraglutide
Semaglutide and liraglutide are lipidated GLP-1 receptor agonists from the same developer, both FDA-approved. This page compares their sequence modifications, albumin-binding chemistry, trial programs, regulatory status and the analytical issues shared by lipidated peptides.
Liraglutide and semaglutide are both analogues of human glucagon-like peptide-1 (GLP-1) developed by Novo Nordisk. Liraglutide came first and showed that attaching a fatty acid to the GLP-1 backbone could extend its time in circulation through reversible binding to serum albumin. Semaglutide was later engineered from the same starting sequence with a different fatty acid side chain and an extra substitution that blocks enzymatic cleavage.
Both act at the GLP-1 receptor and both are approved in the US for type 2 diabetes and for chronic weight management, under different brand names. Because they share a backbone and a mechanism, they are a useful pair for understanding how small changes to lipidation and protease resistance alter the pharmacokinetic profile of a peptide drug.
Side-by-side
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Sequence basis | Human GLP-1(7-37), 31 residues | Human GLP-1(7-37), 31 residues |
| Backbone substitutions | Aib at position 8 and arginine at position 34 | Arginine at position 34; native alanine at position 8 |
| Lipid side chain | C18 fatty diacid on Lys26 via a γ-glutamic acid spacer and hydrophilic linker | C16 palmitic acid on Lys26 via a γ-glutamic acid spacer |
| DPP-4 resistance | Aib at position 8 blocks cleavage directly | Relies mainly on albumin binding and self-association for protection |
| Receptor target | GLP-1 receptor | GLP-1 receptor |
| Developer | Novo Nordisk | Novo Nordisk |
| Major trial programs | SUSTAIN (type 2 diabetes), STEP (obesity), SELECT (cardiovascular outcomes) | LEAD (type 2 diabetes), SCALE (obesity), LEADER (cardiovascular outcomes) |
| FDA status | Approved (Ozempic, Wegovy, Rybelsus) | Approved (Victoza, Saxenda) |
| Analytical pitfalls | Confirm lipidated mass; aggregation; linker-related impurities | Confirm lipidated mass; aggregation; incomplete or misplaced acylation |
| Storage | Lyophilized at -20 °C, protected from light and moisture; avoid freeze-thaw | Lyophilized at -20 °C, protected from light and moisture; avoid freeze-thaw |
Two generations of the same design idea
Native GLP-1 is cleared within minutes because dipeptidyl peptidase-4 (DPP-4) removes its first two residues and the kidney filters the small peptide quickly. Liraglutide addressed this by attaching a palmitic acid to lysine 26, which lets the molecule bind albumin and self-associate, slowing absorption and clearance. Semaglutide kept the same overall strategy but replaced alanine 8 with α-aminoisobutyric acid (Aib) to block DPP-4 directly and used a longer C18 diacid with a hydrophilic linker that binds albumin more strongly. The result is a substantially longer circulating half-life for semaglutide.
Clinical evidence and head-to-head trials
Both compounds have large phase 3 programs and dedicated cardiovascular outcome trials, LEADER for liraglutide and SELECT (with SUSTAIN-6 earlier) for semaglutide. They have also been compared directly. SUSTAIN 10 compared the two in type 2 diabetes, and STEP 8 compared them in adults with obesity without diabetes; in both trials semaglutide produced larger reductions in the primary measures studied. These are human trial results for approved drugs and are summarized here for context only; approved labeling describes the populations and conditions studied.
Analytical considerations for lipidated GLP-1 analogues
Identity testing for either compound should confirm the mass of the complete acylated molecule, not just the peptide backbone, because the side chain is a defined part of the structure. Useful certificates also look for related substances specific to acylation chemistry, such as unacylated peptide, acylation at the wrong lysine or partially built linkers. Both molecules can aggregate or form fibrils, so HPLC purity is ideally supported by a method sensitive to high-molecular-weight species. The sequence analyzer computes backbone masses; the lipid side chain must be added separately.
Frequently asked questions
Are semaglutide and liraglutide the same drug?
No. Both are GLP-1 receptor agonists built on the human GLP-1(7-37) sequence and both were developed by Novo Nordisk, but they differ in structure. Semaglutide has an Aib substitution at position 8 and a C18 fatty diacid side chain with a linker, while liraglutide keeps the native alanine and carries a C16 palmitic acid. These changes give semaglutide a longer half-life.
Are semaglutide and liraglutide FDA approved?
Yes. Semaglutide is approved as Ozempic, Wegovy and Rybelsus, and liraglutide is approved as Victoza and Saxenda. Indications differ by product and include type 2 diabetes and chronic weight management, with cardiovascular risk reduction claims on some labels. Compounding status depends on current FDA guidance, which should be checked directly.
Which has been shown to be more effective in trials?
In head-to-head phase 3 trials, SUSTAIN 10 in type 2 diabetes and STEP 8 in obesity, semaglutide produced larger changes than liraglutide on the primary measures studied. These results apply to the approved products under the trial conditions tested. They do not describe research-grade material, whose identity and purity must be established independently.
Full entries
- Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).
- Liraglutide
Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist with a fatty acid side chain. It is FDA-approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda).
Cite this page